Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
New Study Shows Cannabis Effects on Driving Skills
Publish date: Mar 1, 2013
![]()
PR Newswire WASHINGTON, March 1, 2013
WASHINGTON, March 1, 2013 /PRNewswire/ -- New research
appearing online today in
Clinical Chemistry
, the journal of AACC, shows that cannabis can be
detected in the blood of daily smokers for a month after last intake. The scientific data in this paper by Bergamaschi et
al. can provide real help in the public safety need for a drugged driving policy that reduces the number of drugged driving
accidents on the road. (Logo: http://photos.prnewswire.com/prnh/20121206/PH25333LOGO) Cannabis is second only to alcohol for causing impaired driving and motor vehicle accidents. In 2009, 12.8% of young adults
reported driving under the influence of illicit drugs and in the 2007 National Roadside Survey, more drivers tested positive
for drugs than for alcohol. These cannabis smokers had a 10-fold increase in car crash injury compared with infrequent or
nonusers after adjustment for blood alcohol concentration. In this paper, 30 male chronic daily cannabis smokers resided on a secure research unit for up to 33 days, with daily blood
collection. Twenty-seven of 30 participants were THC-positive on admission, with a median (range) concentration of 1.4 mcg/L
(0.3–6.3). THC decreased gradually with only 1 of 11 participants negative at 26 days; 2 of 5 remained THC-positive
(0.3 mcg/L) for 30 days. These results demonstrate, for the first time, that cannabinoids can be detected in blood of chronic daily cannabis smokers
during a month of sustained abstinence. This is consistent with the time course of persisting neurocognitive impairment reported
in recent studies and suggests that establishment of 'per se' THC legislation might achieve a reduction in motor vehicle injuries
and deaths. This same type of 'per se' alcohol legislation improved prosecution of drunk drivers and dramatically reduced
alcohol-related deaths. "These data have never been obtained previously due to the cost and difficulty of studying chronic daily cannabis smoking
over an extended period," said Dr. Marylin Huestis of the National Institutes of Health and
author on the paper. "These data add critical information to the debate about the toxicity of chronic daily cannabis smoking." Reporters who wish to receive a copy of the study or arrange an interview with the authors may contact Molly
Polen at 202-420-7612 or mpolen@aacc.org.
About AACC The American Association for Clinical Chemistry, AACC, brings together the global laboratory medicine community in the
pursuit of improving health and healthcare through laboratory medicine. With more than 8,500 members including MDs, PhDs,
research scientists, and others involved in developing tests and directing laboratory operations, AACC advances scientific
collaboration, knowledge, expertise and innovation through its many programs, publications and initiatives. For more information,
visit www.aacc.org.
Clinical Chemistry is the leading international journal of clinical laboratory science, providing 2,000 pages per year
of peer-reviewed papers that advance the science of the field. With an impact factor of 7.9, Clinical Chemistry covers
everything from molecular diagnostics to laboratory management. SOURCE AACC
|
|